BioNTech SE
Clinical trials sponsored by BioNTech SE, explained in plain language.
A biotechnology company developing immunotherapies, including mRNA-based vaccines and cancer treatments.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- BioNTech launches first human test of mRNA herpes vaccine Results expected Oct 2026 (estimated)
- New antibody BNT351 enters first human trial for HIV Results expected Nov 2026 (estimated)
- New vaccine aims to stop colorectal cancer recurrence in High-Risk patients Results expected Nov 2026 (estimated) May already have reported ↗
- Can updated COVID-19 shots better protect High-Risk groups? Results expected Apr 2027 (estimated)
- New combo therapy takes on tough lung cancer Results expected Jun 2027 (estimated)
-
New COVID-19 vaccine trial targets variants in Middle-Aged adults
Vaccine OngoingThis study tests a variant-adapted COVID-19 vaccine in about 5,240 healthy adults aged 50 to 64. Half receive the vaccine, half a placebo, to see if it safely prevents COVID-19 caused by new virus variants. The goal is to find out how well the updated shot works in this age group…
Phase 3 • Sponsor: BioNTech SE • Aim: Vaccine
Last updated Jun 27, 2026 12:06 UTC
-
New TB vaccines enter human trials – could they beat the world’s deadliest infection?
Vaccine OngoingThis study tests two experimental vaccines (BNT164a1 and BNT164b1) to see if they are safe and trigger an immune response against tuberculosis. About 500 healthy adults who have already received the BCG vaccine will receive three doses of either a vaccine or a placebo. The goal i…
Phase 1/2 • Sponsor: BioNTech SE • Aim: Vaccine
Last updated Jun 27, 2026 11:03 UTC
-
BioNTech launches first human test of mRNA herpes vaccine
Vaccine OngoingThis early-stage trial tests an mRNA vaccine called BNT163, designed to prevent genital herpes caused by HSV-2 and possibly HSV-1. About 318 healthy adults and people with recurrent genital herpes will receive the vaccine or a placebo. The main goal is to check safety and measure…
Phase 1 • Sponsor: BioNTech SE • Aim: Vaccine
Last updated Jun 27, 2026 07:55 UTC
-
New cancer drug BNT314 enters first human safety trial
Disease control OngoingThis study is the first time BNT314 is being tested in humans. It aims to see if the drug is safe for people with advanced solid tumors that have not responded to other treatments. About 41 participants will receive different doses to find the highest dose that is still safe and …
Phase 1 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New combo therapy takes on tough lung cancer
Disease control OngoingThis Phase 2 trial is testing an experimental drug called BNT327 combined with standard chemotherapy in 110 people with small-cell lung cancer. One group has untreated extensive-stage disease, while others have cancer that returned after prior treatment. The study aims to see if …
Phase 2 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New vaccine plus immunotherapy shows promise against HPV-Linked head and neck cancer
Disease control OngoingThis trial tests whether adding a vaccine called BNT113 to the immunotherapy drug pembrolizumab works better than pembrolizumab alone for people with advanced head and neck cancer linked to HPV16. About 350 participants will receive either the combination or the standard single d…
Phase 2/3 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New vaccine aims to stop colorectal cancer recurrence in High-Risk patients
Disease control OngoingThis study tests an experimental vaccine (RO7198457) in people with stage II or III colorectal cancer who have signs of remaining cancer DNA in their blood after surgery. The goal is to see if the vaccine can prevent the cancer from returning better than simply watching and waiti…
Phase 2 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New hope for hard-to-treat breast cancer: experimental combo shows promise
Disease control OngoingThis study tests a new drug called BNT327, given with chemotherapy, for people with advanced triple-negative breast cancer that has spread. The goal is to see if the combination is safe and shrinks tumors. About 83 adults will take part, and the study is currently active but not …
Phase 2 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC